Characterization of patients with diabetes who were incidentally found to be glutamic acid decarboxylase autoantibody-positive by bridging-type enzyme-linked immunosorbent assay.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Asian Association for the Study of Diabetes and Blackwell Pub. Asia Country of Publication: Japan NLM ID: 101520702 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2040-1124 (Electronic) Linking ISSN: 20401116 NLM ISO Abbreviation: J Diabetes Investig Subsets: MEDLINE
    • Publication Information:
      Original Publication: Tokyo : Asian Association for the Study of Diabetes and Blackwell Pub. Asia
    • Subject Terms:
      Autoantibodies/*blood ; Biomarkers/*blood ; Diabetes Mellitus, Type 2/*immunology ; Glutamate Decarboxylase/*immunology; Adult ; Autoantibodies/immunology ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/epidemiology ; Enzyme-Linked Immunosorbent Assay ; Female ; Follow-Up Studies ; Humans ; Incidental Findings ; Japan/epidemiology ; Male ; Mass Screening ; Middle Aged ; Prognosis
    • Abstract:
      This study aimed to characterize diabetic patients incidentally found to be positive for glutamic acid decarboxylase autoantibodies (GADA) in general practice. Using bridging-type enzyme-linked immunosorbent assay, we screened 1,040 patients with phenotypic type 2 diabetes for GADA, finding 25 (2.4%) to be positive. However, on retesting, with a median interval of 19 days, 44% of GADA-positive patients turned negative (Disappearing Group). The mean age at diabetes onset was significantly higher (P < 0.05) and GADA titers at first determination were significantly lower (P < 0.001) in the Disappearing Group compared with the Persistent Positive Group. On initial screening, all patients in the Disappearing Group had GADA titers of <6.5 U/mL. The current study showed that a portion of phenotypic type 2 diabetic patients incidentally identified as GADA-positive were falsely positive, and that to avoid the misclassification, remeasurement of GADA is essential in cases showing very low titers.
      (© 2020 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.)
    • References:
      Diabetes. 2010 Feb;59(2):416-22. (PMID: 19864397)
      Diabetologia. 2005 Nov;48(11):2195-9. (PMID: 16193287)
      Clin Chim Acta. 2008 Feb;388(1-2):130-4. (PMID: 18023278)
      J Diabetes Investig. 2017 Jul;8(4):475-479. (PMID: 27863109)
      Clin Chim Acta. 2003 May;331(1-2):55-9. (PMID: 12691864)
      J Diabetes Res. 2018 Jul 11;2018:1847430. (PMID: 30116734)
      J Diabetes Investig. 2019 Jul;10(4):990-996. (PMID: 30582775)
      J Diabetes Investig. 2019 May;10(3):685-689. (PMID: 30307126)
    • Contributed Indexing:
      Keywords: Autoantibody; False positive; Slowly-progressive type 1 diabetes
    • Accession Number:
      0 (Autoantibodies)
      0 (Biomarkers)
      EC 4.1.1.15 (Glutamate Decarboxylase)
    • Publication Date:
      Date Created: 20200530 Date Completed: 20210819 Latest Revision: 20210819
    • Publication Date:
      20231215
    • Accession Number:
      PMC7610115
    • Accession Number:
      10.1111/jdi.13307
    • Accession Number:
      32469160